Newsroom | 44039 results

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive bladder cancer (NMIBC). "The early safety profile and clinical activity results fro...

LOS ANGELES--(BUSINESS WIRE)--Researchers with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, will present more than 74 chaired, plenary, educational, minisymposium, poster and other sessions on innovative clinical trial results, breakthrough diagnostic techniques and advances in treatment options at the AACR Annual Meeting, which st...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced late-breaking, one-year clinical trial results for its innovative pulsed field ablation (PFA) device—the Globe PF System. These pivotal findings from the PULSAR IDE study were announced at the Heart Rhythm Society (HRS) meeting in San Diego1, highlighting the safety and efficacy data of the Globe PF System, which is currently...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced o...

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the World Vaccine Congress 2025 on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial infections and its applications in inflammatory diseases. The World Vaccine Congress took place in Washington, D.C. from April 22-24. Sepsis is a life-threatening com...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) kondigde vandaag aan dat het bedrijf nieuwe gegevens uit het vroege stadium uit haar oncologieportfolio zal voorstellen tijdens de Annual Meeting 2025 van de AACR (American Association of Cancer Research) in Chicago, IL, die doorgaat van 25 tot 30 april. “Tijdens AACR zullen we gegevens voorstellen uit programma's van het vroege stadium binnen onze oncologieportfolio, onder andere voor patiënten met myeloproliferatieve neoplasmata, eiersto...

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq : INCY) a annoncé aujourd’hui qu’elle présentera de nouvelles données préliminaires issues de son portefeuille de traitements oncologiques lors du congrès annuel 2025 de l’American Association for Cancer Research (AACR), qui se tiendra à Chicago (Illinois) du 25 au 30 avril. « À l’occasion du congrès de l'AACR, nous dévoilerons des données préliminaires issues de nos programmes cliniques en phase initiale, portant notamment sur les néoplasme...

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass das Unternehmen auf der Jahrestagung 2025 der American Association for Cancer Research (AACR) vom 25. bis 30. April in Chicago, Illinois, neue Daten aus frühen Phasen seines Onkologieportfolios vorstellen wird. „Auf der AACR werden wir Daten aus frühen Programmen unseres Onkologie-Portfolios vorstellen, darunter für Patienten mit myeloproliferativen Neoplasien, Eierstockkrebs und anderen soliden Tumoren“, sagte...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025...

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025...